AzTrials
AzTrials

DeliriumPhase 4DELICATENCT03729011

Delirium Reduction by Volatile Anesthesia in Cardiac Surgery

A Phase 4 study testing Volatile agent and Propofol in people with Delirium, run by Meshalkin Research Institute of Pathology of Circulation at 5 sites in Russia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Parallel group, prospective, randomized, controlled, single-blinded trial. The aim of our study is to test the hypothesis that volatile anesthesia would reduce the incidence of early postoperative delirium in patients undergoing cardiac surgery with CPB as compared to TIVA. Read more about this study

Who is it for?
Ages 65 years and older
Conditions the study is for
Delirium
What is being tested?
Volatile agent and Propofol
Could I receive a placebo?
No, everyone receives an active treatment
How many people
405 participants
Where
5 sitesRussia
Study dates
9 Jan 2019to 11 Jan 2024
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Who may be able to join

  • Males and females > 65 years
  • Written informed consent
  • Cardiac surgery with CPB

Who cannot join

  • Emergency surgery
  • Surgery on aorta
  • Known allergy to components of anaesthesia
  • Pregnancy
  • Hemodynamically significant stenosis of carotid arteries
  • Parkinson's disease
Show all 11Show fewer
  • Liver cirrhosis (Child B or C)
  • Current enrollment into another RCT (in the last 30 days)
  • Previous enrollment and randomization into the DELICATE trial
  • Poor language comprehension
  • Preoperative Medications: Anticholinergics (dimedrol, atropine, dramina), antidepressants, antiepileptics, antiparkinson drugs, chemotherapeutic agents

Trial locations and contacts

5 sites in 1 country.

5 sites in 1 country

Russia5 sites
  • National Medical Research Center for Surgery named after A.V. Vishnevsky, Ministry of Health of the Russian Federation

    Moscow, 117997

  • M.F. Vladimirsky Moscow Regional Research and Clinical Institute (MONIKI)

    Moscow

  • Meshalkin Research Institute of Pathology of Circulation

    Novosibirsk, 630055

  • Saint Petersburg State University Hospital

    Saint Petersburg

  • Tomsk National Research Medical Center of the Russian Academy of Sciences

    Tomsk

Other trials in Russia

About this study

Official title: Delirium Reduction by Volatile Anesthesia in Cardiac Surgery: Prospective, Randomized, Single-blinded Study

Parallel group, prospective, randomized, controlled, single-blinded trial. The aim of our study is to test the hypothesis that volatile anesthesia would reduce the incidence of early postoperative delirium in patients undergoing cardiac surgery with CPB as compared to TIVA.

Read the detailed description

Delirium is a common neurologic complication after cardiac surgery. Up to 52% of postoperative cardiac surgery patients have delirium. The occurrence of postoperative delirium is associated with worse outcomes, including prolonged length of stay in the ICU and hospital, increased morbidity and mortality, compromised long-term cognitive function and physical ability, and elevated medical care costs. Morbidity of postoperative cognitive dysfunction and delirium mostly common in patients with age more than 60 years.

Several factors including cerebral anoxia, embolism, excessive excitatory neurotransmitter release, systemic inflammatory response, electrolyte and metabolic disorders and hemodynamic changes have been demonstrated to contribute to postoperative neurological dysfunction and delirium.

Previous studies have shown that inhalation anaesthesia and total intravenous anaesthesia (TIVA) may produce different degrees of cerebral protection in these patients. Effects of this two types of anaesthesia in cardiac surgery with CPB remain controversial and much debated.

Inhalation agents depress glucose metabolism, decrease cerebral metabolic rate and oxygen consumption. They also partially uncouple the reactivity of cerebral blood flow to CO2. The changes in cerebral blood flow (CBF) depend on the changes in cerebral metabolism and on direct vasodilatory effects. Cerebral autoregulation is dose-dependently altered. Volatile anaesthetics have been shown to initiate early ischemic preconditioning in neurons, but models of focal brain ischemia suggest it can take 24 h for preconditioning to develop fully.

Propofol is a well-known potentiator of GABAA receptors, it reduces cerebrovascular resistance, CBF and cerebral oxygen delivery during cardiopulmonary bypass. A neuroprotective effect of propofol has been shown to be present in many in vitro and in vivo established experimental models of mild/moderate acute cerebral ischemia.

In recent meta-analysis of 13 randomized controlled studies Chen et al compared the neuroprotective effects of inhalational anesthesia and those of total intravenous anesthesia (TIVA) in cardiac surgery with cardiopulmonary bypass. They have shown that anesthesia with volatile agents appeared to provide better cerebral protection than TIVA. As this meta-analysis had several limitations (small sample size of included studies, high heterogenity, etc.), further studies with larger clinically relevant sample-sizes are needed to demonstrate which anesthetics are more beneficial in terms of brain protection in cardiac surgery.

Conditions
Delirium
Being tested
Volatile agent, Propofol
Keywords
delirium, Cardiac surgery, Cardiopulmonary bypass, Cognitive dysfunction
Medical subject headings
Delirium, Cognitive Dysfunction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Volatile agentDrug

    Also called Sevoflurane, Desflurane, Isoflurane

    Patients will receive volatile agent to provide general anaesthesia, including CPB period. Volatile agents will be administered from anesthesia induction to the end of surgery. Concentration (MAC) of volatile agent will be selected by anaesthesiologist according to clinical situation and patient features.

  • PropofolDrug

    Patients will receive propofol and no volatile agent. Propofol will be used for induction and maintenance of anesthesia.

Study groups in NCT03729011
Study groupRoleWhat they receive
Volatile anesthesia groupActive comparatorNot described
Receives: Drug: Volatile agent
TIVA groupActive comparatorNot described
Receives: Drug: Propofol

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Postoperative delirium

    Postoperative delirium detection will be managed with Confusion Assessment Method for the ICU (CAM-ICU)

    Measured: 5 days after surgery

Secondary outcomes (14)
  1. Early postoperative cognitive dysfunction

    We will use Montreal Cognitive Assessment (MoCA) to detect cognitive dysfunction

    Measured: 7 days after surgery

  2. Delirium duration

    number of days

    Measured: 10 days after surgery

  3. Duration of ICU stay

    number of days

    Measured: 30 days

  4. Duration of hospital stay

    number of days

    Measured: 60 days

  5. 30-day all-cause mortality

    yes/no

    Measured: 30 days

  6. One-year all-cause mortality

    yes/no

    Measured: 1 year

  7. Myocardial infarction (MI)

    yes/no

    Measured: 30 days

  8. Stroke

    Stroke will be diagnosed by neurologist (yes/no)

    Measured: 30 days

  9. Seizures

    Presence of Seizures (yes/no)

    Measured: 30 days

  10. Incidence of acute kidney injury (AKI)

    According to KDIGO criteria

    Measured: 30 days

  11. Renal replacement therapy

    We will collect data about need of renal replacement therapy (yes/no)

    Measured: 30 days

  12. Infectious complications

    We will collect data about infectious complications: wound infection, mediastinitis, pneumonia, positive blood culture

    Measured: 30 days

  13. Pain assessment with Behavioral Pain Scale (BPS)

    The BPS is an observational pain scale. It has been validated for use in deeply sedated, mechanically ventilated patients. The BPS contains 3 subscales: facial expression, upper limb movements, and compliance with mechanical ventilation. Each subscale is scored from 1 (no response) to 4 (full response). Therefore, BPS scores range from 3 (no pain) to 12 (maximal pain). A BPS score of 6 or higher is considered to reflect unacceptable pain.

    Measured: 5 days after surgery

  14. Pain assessment with Numerical Rating Scale (NRS)

    A NRS involves asking the patient to rate his or her pain from 0 to 10 (11 point scale) or from 0 to 100 (101 point scale) with the understanding that 0 is equal to no pain and 10 or 100 is equal to worst possible pain.

    Measured: 5 days after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Nov 2018
  2. Study start9 Jan 2019
  3. Primary completion11 Jan 2024
  4. Study completion11 Jan 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
Patients will be randomly allocated to receive either inhalation anaesthesia or TIVA. Permuted-block randomization will be used to allocate subjects to one of the study groups. Sequentially numbered sealed opaque envelopes will contain the treatment code, to be opened in the morning of surgery. Patients will be unaware of group assignment. All the statistical analyses will be performed by the biostatistician not involved in treatment allocation.
Masking
Single blind
Who is masked
Participant
Enrolment
405 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03729011
Sponsor's protocol ID
18
Acronym
DELICATE
Status last verified
Jan 2024
First submitted
3 Oct 2018
Last updated
15 May 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Brown CH. Delirium in the cardiac surgical ICU. Curr Opin Anaesthesiol. 2014 Apr;27(2):117-22. doi: 10.1097/ACO.0000000000000061.

    PubMed 24514034
  • Martin BJ, Buth KJ, Arora RC, Baskett RJ. Delirium: a cause for concern beyond the immediate postoperative period. Ann Thorac Surg. 2012 Apr;93(4):1114-20. doi: 10.1016/j.athoracsur.2011.09.011. Epub 2011 Dec 24.

    PubMed 22200370
  • Gottesman RF, Grega MA, Bailey MM, Pham LD, Zeger SL, Baumgartner WA, Selnes OA, McKhann GM. Delirium after coronary artery bypass graft surgery and late mortality. Ann Neurol. 2010 Mar;67(3):338-44. doi: 10.1002/ana.21899.

    PubMed 20373345
  • Rudolph JL, Inouye SK, Jones RN, Yang FM, Fong TG, Levkoff SE, Marcantonio ER. Delirium: an independent predictor of functional decline after cardiac surgery. J Am Geriatr Soc. 2010 Apr;58(4):643-9. doi: 10.1111/j.1532-5415.2010.02762.x. Epub 2010 Mar 22.

    PubMed 20345866
  • Franco K, Litaker D, Locala J, Bronson D. The cost of delirium in the surgical patient. Psychosomatics. 2001 Jan-Feb;42(1):68-73. doi: 10.1176/appi.psy.42.1.68.

    PubMed 11161124
  • Pisani MA, Kong SY, Kasl SV, Murphy TE, Araujo KL, Van Ness PH. Days of delirium are associated with 1-year mortality in an older intensive care unit population. Am J Respir Crit Care Med. 2009 Dec 1;180(11):1092-7. doi: 10.1164/rccm.200904-0537OC. Epub 2009 Sep 10.

    PubMed 19745202
  • Bickel H, Gradinger R, Kochs E, Forstl H. High risk of cognitive and functional decline after postoperative delirium. A three-year prospective study. Dement Geriatr Cogn Disord. 2008;26(1):26-31. doi: 10.1159/000140804. Epub 2008 Jun 24.

    PubMed 18577850
  • Li YW, Li HJ, Li HJ, Feng Y, Yu Y, Guo XY, Li Y, Zhao BJ, Hu XY, Zuo MZ, Zhang HY, Wang MR, Ji P, Yan XY, Wu YF, Wang DX. Effects of two different anesthesia-analgesia methods on incidence of postoperative delirium in elderly patients undergoing major thoracic and abdominal surgery: study rationale and protocol for a multicenter randomized controlled trial. BMC Anesthesiol. 2015 Oct 13;15:144. doi: 10.1186/s12871-015-0118-5.

    PubMed 26459347
  • Nguyen Q, Uminski K, Hiebert BM, Tangri N, Arora RC. Midterm outcomes after postoperative delirium on cognition and mood in patients after cardiac surgery. J Thorac Cardiovasc Surg. 2018 Feb;155(2):660-667.e2. doi: 10.1016/j.jtcvs.2017.09.131. Epub 2017 Oct 20.

    PubMed 29132782
  • Cerejeira J, Firmino H, Vaz-Serra A, Mukaetova-Ladinska EB. The neuroinflammatory hypothesis of delirium. Acta Neuropathol. 2010 Jun;119(6):737-54. doi: 10.1007/s00401-010-0674-1. Epub 2010 Mar 24.

    PubMed 20309566
  • Caplan JP, Chang G. Refeeding syndrome as an iatrogenic cause of delirium: a retrospective pilot study. Psychosomatics. 2010 Sep-Oct;51(5):419-24. doi: 10.1176/appi.psy.51.5.419.

    PubMed 20833941
  • Siepe M, Pfeiffer T, Gieringer A, Zemann S, Benk C, Schlensak C, Beyersdorf F. Increased systemic perfusion pressure during cardiopulmonary bypass is associated with less early postoperative cognitive dysfunction and delirium. Eur J Cardiothorac Surg. 2011 Jul;40(1):200-7. doi: 10.1016/j.ejcts.2010.11.024. Epub 2010 Dec 18.

    PubMed 21168339
  • Hshieh TT, Fong TG, Marcantonio ER, Inouye SK. Cholinergic deficiency hypothesis in delirium: a synthesis of current evidence. J Gerontol A Biol Sci Med Sci. 2008 Jul;63(7):764-72. doi: 10.1093/gerona/63.7.764.

    PubMed 18693233
  • Wimmer-Greinecker G, Matheis G, Brieden M, Dietrich M, Oremek G, Westphal K, Winkelmann BR, Moritz A. Neuropsychological changes after cardiopulmonary bypass for coronary artery bypass grafting. Thorac Cardiovasc Surg. 1998 Aug;46(4):207-12. doi: 10.1055/s-2007-1010226.

    PubMed 9776494
  • Chen F, Duan G, Wu Z, Zuo Z, Li H. Comparison of the cerebroprotective effect of inhalation anaesthesia and total intravenous anaesthesia in patients undergoing cardiac surgery with cardiopulmonary bypass: a systematic review and meta-analysis. BMJ Open. 2017 Oct 11;7(10):e014629. doi: 10.1136/bmjopen-2016-014629.

    PubMed 29025825

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Volatile agent and Propofol in people with Delirium, run by Meshalkin Research Institute of Pathology of Circulation at 5 sites in Russia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 May 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Postoperative delirium (time frame: 5 days after surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03729011, which also lists 24 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in